Archive

Neovasc Announces Presentations on Tiara™ for Treatment of Mitral Regurgitation and Reducer™ for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference

Posted on June 27, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, June 27, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...

Read More

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

Posted on June 25, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, June 25, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More

Tiara™ Featured in Presentation at 11th Annual TVT 2019

Posted on June 17, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, June 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More

Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology

Posted on May 22, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, May 22, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More